Publication

Hydrogen Sulfide Is a Novel Regulator of Bone Formation Implicated in the Bone Loss Induced by Estrogen Deficiency

Downloadable Content

Persistent URL
Last modified
  • 03/03/2025
Type of Material
Authors
    Francesco Grassi, Laboratorio Ramses Istituto Ortopedico RizzoliAbdul Malik Tyagi, Emory UniversityJohn Calvert, Emory UniversityLaura Gambari, Laboratorio Ramses Istituto Ortopedico RizzoliLindsey D Walker, Emory UniversityMingcan Yu, Emory UniversityJerid Robinson, Emory UniversityJau-Yi Li, Emory UniversityGina Lisignoli, Laboratorio Ramses Istituto Ortopedico RizzoliChiara Vaccaro, Emory UniversityJonathan Adams, Emory UniversityRoberto Pacifici, Emory University
Language
  • English
Date
  • 2016-05-01
Publisher
  • American Society for Bone and Mineral Research
Publication Version
Copyright Statement
  • © 2015 American Society for Bone and Mineral Research.
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0884-0431
Volume
  • 31
Issue
  • 5
Start Page
  • 949
End Page
  • 963
Grant/Funding Information
  • This study was supported by grants from the National Institutes of Health (DK91780, DK007298, and RR028009) and by grant ‘Ricerca Finalizzata’ from the Italian Ministry of Health (RF PE-2011-02348395).
  • LG was supported by a fellowship granted by Spinner 2013.
  • JYL was supported by a grant from the National Institutes of Health (AR061453).
Supplemental Material (URL)
Abstract
  • Hydrogen sulfide (H2S) is a gasotransmitter known to regulate bone formation and bone mass in unperturbed mice. However, it is presently unknown whether H2S plays a role in pathologic bone loss. Here we show that ovariectomy (ovx), a model of postmenopausal bone loss, decreases serum H2S levels and the bone marrow (BM) levels of two key H2S-generating enzymes, cystathione β-synthase (CBS) and cystathione γ-lyase (CSE). Treatment with the H2S-donor GYY4137 (GYY) normalizes serum H2S in ovx mice, increases bone formation, and completely prevents the loss of trabecular bone induced by ovx. Mechanistic studies revealed that GYY increases murine osteoblastogenesis by activating Wnt signaling through increased production of the Wnt ligands Wnt16, Wnt2b, Wnt6, and Wnt10b in the BM. Moreover, in vitro treatment with 17β-estradiol upregulates the expression of CBS and CSE in human BM stromal cells (hSCs), whereas an H2S-releasing drug induces osteogenic differentiation of hSCs. In summary, regulation of H2S levels is a novel mechanism by which estrogen stimulates osteoblastogenesis and bone formation in mice and human cells. Blunted production of H2S contributes to ovx-induced bone loss in mice by limiting the compensatory increase in bone formation elicited by ovx. Restoration of H2S levels is a potential novel therapeutic approach for postmenopausal osteoporosis.
Author Notes
  • Roberto Pacifici, MD, Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, 101 Woodruff Circle, Room 1309, Atlanta, GA 30322, USA roberto.pacifici@emory.edu
Keywords
Research Categories
  • Health Sciences, Obstetrics and Gynecology
  • Biology, Microbiology

Tools

Relations

In Collection:

Items